News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

43% Relative Improvement Versus Control Group In Hard-To-Heal Venous Leg Ulcers Obtained With XCELLentis' LyphoDerm(TM)



10/19/2005 5:10:24 PM

XCELLentis, a wholly owned subsidiary of Innogenetics, today announced the top line results of its open-label phase 2 clinical trial with LyphoDermâ„¢ for the treatment of hard-to-heal venous leg ulcers.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES